Investors of Y-mAbs Therapeutics, Encouraged to Take Action After Sustaining Losses
January 30, 2023
Trending News 🌧️
Y-MABS ($NASDAQ:YMAB): Investors of Y-mAbs Therapeutics, Inc., a biopharmaceutical company, have recently been encouraged to take action after sustaining losses. The Schall Law Firm is issuing an action alert for shareholders of Y-mAbs Therapeutics, Inc. who have incurred losses and are interested in exploring their legal options. Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibody-based therapies for the treatment of cancer. The company uses its proprietary antibody-based platform technologies to develop novel therapeutics to target tumor-associated antigens expressed on solid tumors. Its lead product candidate, omburtamab, is being developed in combination with other agents as a treatment for pediatric patients with relapsed or refractory neuroblastoma. The Schall Law Firm is encouraging Y-mAbs Therapeutics, Inc. shareholders to contact their firm if they wish to discuss their legal rights.
The firm specializes in representing shareholders and investors in various types of legal claims including violations of the securities laws. The attorneys at the firm have extensive experience in securities class actions and other complex litigation. The firm is offering free consultations and evaluations to those who have been affected by the company’s actions and believe they may have a valid claim. Shareholders who have questions or concerns about their rights can contact the Schall Law Firm to discuss their legal options.
Market Price
Despite the news coverage of the company mostly being positive, the stock opened at $4.8 and closed at $4.6, a decrease of 3.8% from the last closing price of 4.7. Investors should conduct their own research and analysis of Y-mAbs Therapeutics and its current stock value before making any decisions moving forward. They should consider the company’s fundamentals and financials, as well as any potential risks or changes in the market that might have affected the stock price. It is important to understand why the stock has decreased, and if this trend may continue moving forward.
Ultimately, investors should decide if they would like to remain invested in Y-mAbs Therapeutics or if they should exit their positions. For those who are still interested in investing, it is important to remain informed about market trends and Y-mAbs Therapeutics’ news coverage. By taking the necessary steps to stay up to date, investors can make the most informed decisions for their portfolios. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Y-mabs Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 43.42 | -133.62 | -307.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Y-mabs Therapeutics. More…
| Operations | Investing | Financing |
| -101.12 | -0.46 | 0.18 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Y-mabs Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 143.91 | 36.02 | 2.47 |
Key Ratios Snapshot
Some of the financial key ratios for Y-mabs Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -298.1% |
| FCF Margin | ROE | ROA |
| -234.0% | -67.6% | -56.2% |
VI Analysis
Y-MABS THERAPEUTICS is a company whose fundamentals reflect its long-term potential. The VI Star Chart gives Y-MABS THERAPEUTICS an intermediate health score of 4/10, indicating that it could sustain future operations in times of crisis. It is strong in assets and growth, but weak in dividends and profitability. Y-MABS THERAPEUTICS is classified as a ‘rhino’ – a company that has achieved moderate revenue or earnings growth. Investors who are looking for long-term stability and moderate growth may be interested in Y-MABS THERAPEUTICS. This type of investor may also be looking for companies that are well-positioned to weather future economic downturns. Y-MABS THERAPEUTICS’ intermediate health score gives it an edge over other companies that may experience difficulties if the economy takes a turn for the worse. Additionally, Y-MABS THERAPEUTICS’ assets and growth indicate that it has the potential to continue to perform well even in times of uncertainty. Overall, Y-MABS THERAPEUTICS is a company with moderate growth potential and strong fundamentals. Its intermediate health score shows that it could be a good choice for investors who are looking for stability and moderate returns. Additionally, its assets and growth make it well-positioned to withstand future economic downturns. More…
VI Peers
The company’s lead product candidate, naxitamab, is in clinical development for the treatment of neuroblastoma, a rare and aggressive pediatric cancer. Y-mAbs Therapeutics Inc’s other product candidates are in clinical and preclinical development for the treatment of solid tumors and blood cancers. The company’s competitors include BioAtla Inc, Adagio Therapeutics Inc, and Orphazyme AS.
– BioAtla Inc ($NASDAQ:BCAB)
BioAtla Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of immuno-oncology agents. The company’s market cap as of 2022 is 357.65M and its ROE is -41.59%. BioAtla’s main competitors are Bluebird bio, Inc. (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG).
– Adagio Therapeutics Inc ($NASDAQ:ADGI)
Orphazyme AS is a biotech company that focuses on developing treatments for rare diseases. The company has a market cap of 5.88M as of 2022 and a Return on Equity of -845.21%. Despite its negative ROE, Orphazyme AS’s market cap indicates that investors are confident in the company’s future prospects. This is likely due to the fact that Orphazyme AS is working on developing treatments for rare diseases, which is a highly lucrative market.
Summary
Y-mAbs Therapeutics, Inc. has recently been in the news for its investors suffering losses. Although news coverage has been mostly positive, the stock price dropped on the same day, prompting investors to take action. It is important for investors to thoroughly analyze the company before investing, considering its financials, management team, and competitive landscape. Additionally, investors should be aware of any potential risks or challenges that may arise while investing in Y-mAbs Therapeutics, Inc. and prepare accordingly.
